This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dvorchik, B. H.
Right arrow Articles by Arbeit, R. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dvorchik, B. H.
Right arrow Articles by Arbeit, R. D.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, April 2003, p. 1318-1323, Vol. 47, No. 4
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.4.1318-1323.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Daptomycin Pharmacokinetics and Safety following Administration of Escalating Doses Once Daily to Healthy Subjects

Barry H. Dvorchik,* David Brazier, Michael F. DeBruin, and Robert D. Arbeit

Cubist Pharmaceuticals, Inc., Lexington, Massachusetts

Received 6 May 2002/ Returned for modification 26 July 2002/ Accepted 25 November 2002

The purpose of this paper is to establish the pharmacokinetics and safety of escalating, once-daily doses of daptomycin, a novel lipopeptide antibiotic active against gram-positive pathogens, including those resistant to methicillin and vancomycin. This phase 1, multiple-dose, double-blind study involved 24 healthy subjects in three dose cohorts (4, 6, and 8 mg/kg of body weight) who were randomized to receive daptomycin or the control at a 3:1 ratio and administered the study medication by a 30-min intravenous infusion every 24 h for 7 to 14 days. Daptomycin pharmacokinetics was assessed by blood and urine sampling. Safety and tolerability were evaluated by monitoring adverse events (AEs) and laboratory parameters. Daptomycin pharmacokinetics was linear through 6 mg/kg, with a slight (~20%) nonlinearity in the area under the curve and trough concentration at the highest dose studied (8 mg/kg). The pharmacokinetic parameters measured on the median day of the study period, (day 7) were half-life (~9 h), volume of distribution (~0.1 liters/kg), systemic clearance (~8.2 ml/h/kg), and percentage of the drug excreted intact in urine from 0 to 24 h (~54%). Daptomycin protein binding (mean amount bound, 91.7%) was independent of the drug concentration. No gender effect was observed. All subjects who received daptomycin completed the study. The frequencies and distributions of treatment-emergent AEs were similar for the subjects who received daptomycin and the control subjects. There were no serious AEs and no pattern of dose-related events. The pharmacokinetics of once-daily administration of daptomycin was linear through 6 mg/kg. For all three doses, plasma daptomycin concentrations were consistent and predictable throughout the dosing interval. Daptomycin was well tolerated when it was administered once daily at a dose as high as 8 mg/kg for 14 days.

* Corresponding author. Mailing address: Cubist Pharmaceuticals, Inc., 65 Hayden Ave., Lexington, MA 02421. Phone: (781) 860-8333. Fax: (781) 861-0556. E-mail: bdvorchik{at}cubist.com.

Antimicrobial Agents and Chemotherapy, April 2003, p. 1318-1323, Vol. 47, No. 4
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.4.1318-1323.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Kielstein, J. T., Eugbers, C., Bode-Boeger, S. M., Martens-Lobenhoffer, J., Haller, H., Joukhadar, C., Traunmuller, F., Knitsch, W., Hafer, C., Burkhardt, O. (2009). Dosing of daptomycin in intensive care unit patients with acute kidney injury undergoing extended dialysis--a pharmacokinetic study. Nephrol Dial Transplant 0: gfp704v1-gfp704 [Abstract] [Full Text]  
  • Salama, N. N., Segal, J. H., Churchwell, M. D., Patel, J. H., Gao, L., Heung, M., Mueller, B. A. (2009). Single-dose daptomycin pharmacokinetics in chronic haemodialysis patients. Nephrol Dial Transplant 0: gfp655v1-gfp655 [Abstract] [Full Text]  
  • Schutt, A. C, Bohm, N. M (2009). Multidrug-Resistant Enterococcus faecium Endocarditis Treated with Combination Tigecycline and High-Dose Daptomycin. The Annals of Pharmacotherapy 43: 2108-2112 [Abstract] [Full Text]  
  • Bowker, K. E., Noel, A. R., MacGowan, A. P. (2009). Comparative antibacterial effects of daptomycin, vancomycin and teicoplanin studied in an in vitro pharmacokinetic model of infection. J Antimicrob Chemother 64: 1044-1051 [Abstract] [Full Text]  
  • Smirnova, M. V., Vostrov, S. N., Strukova, E. V., Dovzhenko, S. A., Kobrin, M. B., Portnoy, Y. A., Zinner, S. H., Firsov, A. A. (2009). The impact of duration of antibiotic exposure on bacterial resistance predictions using in vitro dynamic models. J Antimicrob Chemother 64: 815-820 [Abstract] [Full Text]  
  • LaPlante, K. L., Sakoulas, G. (2009). Evaluating Aztreonam and Ceftazidime Pharmacodynamics with Escherichia coli in Combination with Daptomycin, Linezolid, or Vancomycin in an In Vitro Pharmacodynamic Model. Antimicrob. Agents Chemother. 53: 4549-4555 [Abstract] [Full Text]  
  • LaPlante, K. L., Woodmansee, S. (2009). Activities of Daptomycin and Vancomycin Alone and in Combination with Rifampin and Gentamicin against Biofilm-Forming Methicillin-Resistant Staphylococcus aureus Isolates in an Experimental Model of Endocarditis. Antimicrob. Agents Chemother. 53: 3880-3886 [Abstract] [Full Text]  
  • Finegold, S. M., Bolanos, M., Sumannen, P. H., Molitoris, D. R. (2009). In Vitro Activities of Telavancin and Six Comparator Agents against Anaerobic Bacterial Isolates. Antimicrob. Agents Chemother. 53: 3996-4001 [Abstract] [Full Text]  
  • Chakraborty, A., Roy, S., Loeffler, J., Chaves, R. L. (2009). Comparison of the pharmacokinetics, safety and tolerability of daptomycin in healthy adult volunteers following intravenous administration by 30 min infusion or 2 min injection. J Antimicrob Chemother 64: 151-158 [Abstract] [Full Text]  
  • John, A.-K., Baldoni, D., Haschke, M., Rentsch, K., Schaerli, P., Zimmerli, W., Trampuz, A. (2009). Efficacy of Daptomycin in Implant-Associated Infection Due to Methicillin-Resistant Staphylococcus aureus: Importance of Combination with Rifampin. Antimicrob. Agents Chemother. 53: 2719-2724 [Abstract] [Full Text]  
  • Salama, N. N., Segal, J. H., Churchwell, M. D., Patel, J. H., Gao, L., Heung, M., Mueller, B. A. (2009). Intradialytic Administration of Daptomycin in End Stage Renal Disease Patients on Hemodialysis. CJASN 4: 1190-1194 [Abstract] [Full Text]  
  • Moise, P. A, Hershberger, E., Amodio-Groton, M. I, Lamp, K. C (2009). Safety and Clinical Outcomes when Utilizing High-Dose (>=8 mg/kg) Daptomycin Therapy. The Annals of Pharmacotherapy 43: 1211-1219 [Abstract] [Full Text]  
  • Weiss, E. C., Spencer, H. J., Daily, S. J., Weiss, B. D., Smeltzer, M. S. (2009). Impact of sarA on Antibiotic Susceptibility of Staphylococcus aureus in a Catheter-Associated In Vitro Model of Biofilm Formation. Antimicrob. Agents Chemother. 53: 2475-2482 [Abstract] [Full Text]  
  • Chambers, H. F., Basuino, L., Diep, B. A., Steenbergen, J., Zhang, S., Tattevin, P., Alder, J. (2009). Relationship between Susceptibility to Daptomycin In Vitro and Activity In Vivo in a Rabbit Model of Aortic Valve Endocarditis. Antimicrob. Agents Chemother. 53: 1463-1467 [Abstract] [Full Text]  
  • Bubalo, J. S., Munar, M. Y., Cherala, G., Hayes-Lattin, B., Maziarz, R. (2009). Daptomycin Pharmacokinetics in Adult Oncology Patients with Neutropenic Fever. Antimicrob. Agents Chemother. 53: 428-434 [Abstract] [Full Text]  
  • Kim, A., Suecof, L. A., Sutherland, C. A., Gao, L., Kuti, J. L., Nicolau, D. P. (2008). In Vivo Microdialysis Study of the Penetration of Daptomycin into Soft Tissues in Diabetic versus Healthy Volunteers. Antimicrob. Agents Chemother. 52: 3941-3946 [Abstract] [Full Text]  
  • Seaton, R. A. (2008). Daptomycin: rationale and role in the management of skin and soft tissue infections. J Antimicrob Chemother 62: iii15-iii23 [Abstract] [Full Text]  
  • Spanjaard, L., Vandenbroucke-Grauls, C. M. J. E. (2008). Activity of Daptomycin against Listeria monocytogenes Isolates from Cerebrospinal Fluid. Antimicrob. Agents Chemother. 52: 1850-1851 [Abstract] [Full Text]  
  • Mohr, J. F. III, Ostrosky-Zeichner, L., Wainright, D. J., Parks, D. H., Hollenbeck, T. C., Ericsson, C. D. (2008). Pharmacokinetic Evaluation of Single-Dose Intravenous Daptomycin in Patients with Thermal Burn Injury. Antimicrob. Agents Chemother. 52: 1891-1893 [Abstract] [Full Text]  
  • Burkhardt, O., Joukhadar, C., Traunmuller, F., Hadem, J., Welte, T., Kielstein, J. T. (2008). Elimination of daptomycin in a patient with acute renal failure undergoing extended daily dialysis. J Antimicrob Chemother 61: 224-225 [Full Text]  
  • Quinn, B., Hussain, S., Malik, M., Drlica, K., Zhao, X. (2007). Daptomycin inoculum effects and mutant prevention concentration with Staphylococcus aureus. J Antimicrob Chemother 60: 1380-1383 [Abstract] [Full Text]  
  • Rose, W. E., Rybak, M. J., Kaatz, G. W. (2007). Evaluation of daptomycin treatment of Staphylococcus aureus bacterial endocarditis: an in vitro and in vivo simulation using historical and current dosing strategies. J Antimicrob Chemother 60: 334-340 [Abstract] [Full Text]  
  • Pai, M. P., Norenberg, J. P., Anderson, T., Goade, D. W., Rodvold, K. A., Telepak, R. A., Mercier, R.-C. (2007). Influence of Morbid Obesity on the Single-Dose Pharmacokinetics of Daptomycin. Antimicrob. Agents Chemother. 51: 2741-2747 [Abstract] [Full Text]  
  • Cafini, F., Aguilar, L., Gonzalez, N., Gimenez, M. J., Torrico, M., Alou, L., Sevillano, D., Vallejo, P., Prieto, J. (2007). In vitro effect of the presence of human albumin or human serum on the bactericidal activity of daptomycin against strains with the main resistance phenotypes in Gram-positives. J Antimicrob Chemother 59: 1185-1189 [Abstract] [Full Text]  
  • Firsov, A. A., Smirnova, M. V., Lubenko, I. Yu., Vostrov, S. N., Portnoy, Y. A., Zinner, S. H. (2006). Testing the mutant selection window hypothesis with Staphylococcus aureus exposed to daptomycin and vancomycin in an in vitro dynamic model. J Antimicrob Chemother 58: 1185-1192 [Abstract] [Full Text]  
  • Vouillamoz, J., Moreillon, P., Giddey, M., Entenza, J. M. (2006). Efficacy of daptomycin in the treatment of experimental endocarditis due to susceptible and multidrug-resistant enterococci. J Antimicrob Chemother 58: 1208-1214 [Abstract] [Full Text]  
  • Benvenuto, M., Benziger, D. P., Yankelev, S., Vigliani, G. (2006). Pharmacokinetics and Tolerability of Daptomycin at Doses up to 12 Milligrams per Kilogram of Body Weight Once Daily in Healthy Volunteers. Antimicrob. Agents Chemother. 50: 3245-3249 [Abstract] [Full Text]  
  • Leuthner, K. D., Cheung, C. M., Rybak, M. J. (2006). Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus. J Antimicrob Chemother 58: 338-343 [Abstract] [Full Text]  
  • Pai, M. P, Mercier, R.-C., Allen, S. E (2006). Using Vancomycin Concentrations for Dosing Daptomycin in a Morbidly Obese Patient with Renal Insufficiency. The Annals of Pharmacotherapy 40: 553-558 [Abstract] [Full Text]  
  • Rouse, M. S., Piper, K. E., Jacobson, M., Jacofsky, D. J., Steckelberg, J. M., Patel, R. (2006). Daptomycin treatment of Staphylococcus aureus experimental chronic osteomyelitis. J Antimicrob Chemother 57: 301-305 [Abstract] [Full Text]  
  • Huang, V., Rybak, M. J. (2006). Evaluation of daptomycin activity against Staphylococcus aureus in an in vitro pharmacodynamic model under normal and simulated impaired renal function. J Antimicrob Chemother 57: 116-121 [Abstract] [Full Text]  
  • Schriever, C. A., Fernandez, C., Rodvold, K. A., Danziger, L. H. (2005). Daptomycin: A novel cyclic lipopeptide antimicrobial. Am J Health Syst Pharm 62: 1145-1158 [Abstract] [Full Text]  
  • Schriever, C., Zeitz-Colaizzi, L., Quinn, A., Schriever, A. E., Cannon, J. P. (2005). Considerations for the Management of Gram-Positive Pathogens in the Intensive Care Unit. Journal of Pharmacy Practice 18: 100-108 [Abstract]  
  • Echevarria, K., Datta, P., Cadena, J., Lewis, J. S. II (2005). Severe myopathy and possible hepatotoxicity related to daptomycin. J Antimicrob Chemother 55: 599-600 [Full Text]  
  • Dvorchik, B. H., Damphousse, D. (2005). The Pharmacokinetics of Daptomycin in Moderately Obese, Morbidly Obese, and Matched Nonobese Subjects. J Clin Pharmacol 45: 48-56 [Abstract] [Full Text]  
  • Dvorchik, B., Arbeit, R. D., Chung, J., Liu, S., Knebel, W., Kastrissios, H. (2004). Population Pharmacokinetics of Daptomycin. Antimicrob. Agents Chemother. 48: 2799-2807 [Abstract] [Full Text]  
  • Dvorchik, B. (2004). Moderate Liver Impairment Has No Influence on Daptomycin Pharmacokinetics. J Clin Pharmacol 44: 715-722 [Abstract] [Full Text]  
  • Dvorchik, B., Damphousse, D. (2004). Single-Dose Pharmacokinetics of Daptomycin in Young and Geriatric Volunteers. J Clin Pharmacol 44: 612-620 [Abstract] [Full Text]  
  • Streit, J. M., Jones, R. N., Sader, H. S. (2004). Daptomycin activity and spectrum: a worldwide sample of 6737 clinical Gram-positive organisms. J Antimicrob Chemother 53: 669-674 [Abstract] [Full Text]  
  • Alder, J., Li, T., Yu, D., Morton, L., Silverman, J., Zhang, X.-X., Critchley, I., Thorne, G. (2003). Analysis of Daptomycin Efficacy and Breakpoint Standards in a Murine Model of Enterococcus faecalis and Enterococcus faecium Renal Infection. Antimicrob. Agents Chemother. 47: 3561-3566 [Abstract] [Full Text]  
  • (2003). Daptomycin. JWatch Infect. Diseases 2003: 4-4 [Full Text]  


Copyright © 2010 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»